The market isn't just a playground for mega-caps. This week, I've noticed capital drifting into the market's fringes—highly specialized micro-caps and niche financial vehicles. According to people familiar with the matter, these assets are undergoing their most significant overhaul since 2024, from AI workplace startups fighting for survival to a quiet boom in private credit.

CXApp (CXAI.US)

CXApp has been teetering on the edge of delisting, but a recent 1-for-50 reverse stock split has temporarily saved its spot on the Nasdaq, amidst wild fluctuations this year. I'm told the management's main trump card is a new enterprise agentic layer called CXAI 2.0. With the recent acquisition of EngineRoom, the company expects to push its annual recurring revenue (ARR) above USD 12M. This could be the company's most critical test before the next earnings.

Summit Therapeutics (SMMT.US)

Even though its lead candidate Ivonescimab secured a third indication approval in China in August 2026, Summit's stock still saw a notable pullback recently. According to people familiar with the matter, Wall Street is concerned about updated data showing the progression-free survival (PFS) risk reduction shrinking from 40% to 28%, which could complicate the drug's path to approval in Western markets.

Blackstone Secured Lending Fund (BXSL.US)

This Blackstone BDC is a quiet winner in the private credit boom, charting a steady course recently. Its portfolio's fair value reached USD 13.1B by late 2024, and Moody's recently upgraded its rating to Baa2. I'm told its 11.5% annualized dividend yield is attracting a wave of institutional money seeking safe-haven returns.

Avantor (AVTR.US)

As a key supplier to the biopharma industry, Avantor's recovery has been somewhat sluggish, with its stock underperforming the broader market. Net sales for Q2 dropped 2.4% year-over-year to USD 1.7B. However, individuals close to the company indicate that the decline in its biosciences product segment has narrowed to 0.5%, and management is planning a new round of cost optimizations later this year.

RadNet (RDDC.US)

RadNet's network of outpatient imaging centers is accelerating its integration with AI. Total revenue hit a record USD 459.7M in Q2 2024, while its digital health segment surged 36.4%. I'm told its DeepHealth subsidiary just completed the acquisition of iCAD and is integrating ultrasound workflows with Siemens Healthineers, marking the most significant AI deployment in this sub-sector.

Also

• Moleculin Biotech (MBRX.US): Its AML drug Annamycin is advancing in Phase III trials, with recent interim data showing a 62% complete remission rate. Definitely one to watch later this year.
• PIMCO Corporate & Income Opportunity Fund (PTY.US): Maintaining a TTM dividend yield over 12%, this closed-end fund saw a massive jump in net income recently, cementing its status as a defensive high-yield play.
• Franklin FTSE South Korea ETF (FLKR.US): Heavily weighted toward Samsung and SK Hynix, this ETF has faced headwinds recently amid tech volatility. I'm told external investors are actively reassessing the Korean semiconductor supply chain.
• Vonage (VG.US): With limited independent news since its acquisition by Ericsson, people familiar with the matter say the parent company is accelerating the integration of Vonage's APIs into its core network services.
• Direxion Daily Gold Miners Index Bear 2X Shares (DUST.US): Extreme volatility in the gold mining sector recently has turned this 2x leveraged inverse ETF into a highly active trading vehicle for hedging funds.

This article does not constitute investment advice.